Why the study?
Current treatments for joint diseases fail to provide comprehensive and long-term relief, while challenges such as transduction efficiency, off-targets, and preexisting immune responses persist for intra-articular AAV gene therapy.
This review highlights the barriers to intra-articular AAV gene therapy for joint diseases and outlines strategies to improve its efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) conducted a review in Joint diseases. Adeno-associated virus (AAV) gene therapy was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: